152 related articles for article (PubMed ID: 25096922)
1. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
[TBL] [Abstract][Full Text] [Related]
2. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.
Komenda M; Stadler D; Malinas T; Moses M; Pragst I; Herzog E; Schmutz P; Minnig K; El Menyawi I
Vox Sang; 2014 Jul; 107(1):26-36. PubMed ID: 24329163
[TBL] [Abstract][Full Text] [Related]
4. A new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations.
Park DH; Kang GB; Kang DE; Hong JW; Lee MG; Kim KY; Han JW
Biologicals; 2017 Jan; 45():1-8. PubMed ID: 27876270
[TBL] [Abstract][Full Text] [Related]
5. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.
Etscheid M; Breitner-Ruddock S; Gross S; Hunfeld A; Seitz R; Dodt J
Vox Sang; 2012 Jan; 102(1):40-6. PubMed ID: 21545600
[TBL] [Abstract][Full Text] [Related]
6. Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography.
Seifner A; Beck G; Bayer P; Eichmeir S; Lackner F; Rögelsperger O; Weber K; Wollein G
Transfusion; 2014 Feb; 54(2):376-83. PubMed ID: 23772713
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of residual procoagulants in human intravenous immunoglobulins from 11 Chinese blood fractionation companies.
Ma L; Sun P; Lin F; Diao G; Li C
Thromb Res; 2013 Sep; 132(3):381-5. PubMed ID: 23953595
[TBL] [Abstract][Full Text] [Related]
8. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.
Wolberg AS; Kon RH; Monroe DM; Hoffman M
Am J Hematol; 2000 Sep; 65(1):30-4. PubMed ID: 10936860
[TBL] [Abstract][Full Text] [Related]
9. Absence of in vitro Procoagulant Activity in Immunoglobulin Preparations due to Activated Coagulation Factors.
Oviedo AE; Bernardi ME; Guglielmone HA; Vitali MS
Transfus Med Hemother; 2015 Nov; 42(6):397-402. PubMed ID: 26733772
[TBL] [Abstract][Full Text] [Related]
10. Quantitative determination of activated coagulation factor XI as an impurity in therapeutic immunoglobulins from Chinese blood fractionation companies.
Ma L; Sun P; Lin FZ; Diao G; Li CQ
Genet Mol Res; 2013 Jul; 12(3):2556-61. PubMed ID: 23315876
[TBL] [Abstract][Full Text] [Related]
11. Thromboembolic events associated with immunoglobulin treatment.
Funk MB; Gross N; Gross S; Hunfeld A; Lohmann A; Guenay S; Hanschmann KM; Keller-Stanislawski B
Vox Sang; 2013 Jul; 105(1):54-64. PubMed ID: 23398249
[TBL] [Abstract][Full Text] [Related]
12. Significance of platelet and monocyte activation for therapeutic immunoglobulin-induced thromboembolism.
Salge-Bartels U; Heiden M; Groß N; Seitz R
Thromb Res; 2014 Feb; 133(2):244-53. PubMed ID: 24342536
[TBL] [Abstract][Full Text] [Related]
13. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases.
Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S
Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294
[TBL] [Abstract][Full Text] [Related]
14. One IVIG mystery solved, another demands vigilance.
Thompson CA
Am J Health Syst Pharm; 2012 Feb; 69(4):271-2. PubMed ID: 22302248
[No Abstract] [Full Text] [Related]
15. Hemolysis upon intravenous immunoglobulin transfusion.
Padmore RF
Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
[TBL] [Abstract][Full Text] [Related]
16. Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products.
Wilmot HV; Gray E
Vox Sang; 2021 Jul; 116(6):656-664. PubMed ID: 33277936
[TBL] [Abstract][Full Text] [Related]
17. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
Duellberg C; Hannappel A; Kistner S; Maneg O
Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
[TBL] [Abstract][Full Text] [Related]
18. Determination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Behr-Gross ME; Le Tallec D; Sinitskaya N; Milne C; Etscheid M
Pharmeur Bio Sci Notes; 2024; 2024():27-75. PubMed ID: 38533680
[TBL] [Abstract][Full Text] [Related]
19. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
Berger M
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
[TBL] [Abstract][Full Text] [Related]
20. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
Misbah SA
J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
